Non-Myeloablative Allogeneic Transplant for Myelodysplastic Syndromes and Myeloproliferative Disorders

Not Recruiting

Trial ID: NCT00186576

Age - 18 Years-75 Years Condition - Blood and Marrow Transplant (BMT), Myelodysplastic Syndromes (MDS), Myeloproliferative Neoplasm (MPN) Gender - All Accepting Healthy Volunteers - No

Purpose

To improve survival outcomes for patients with MDS and MPD with a nonmyeloablative allogeneic hematopoietic cell transplant.

Official Title

Non-Myeloablative Allogeneic Hematopoietic Cell Transplantation for Treatment of Myelodysplastic Syndromes and Myeloproliferative Disorders (Except CML)

Stanford Investigator(s)

Laura Johnston
Laura Johnston

Professor of Medicine (Blood and Marrow Transplantation and Cellular Therapy)

Robert Negrin
Robert Negrin

Professor of Medicine (Blood and Marrow Transplantation and Cellular Therapy)

Eligibility


Inclusion Criteria:- Myelodysplastic Syndromes

   - Myeloproliferative Disorders

   - HLA matched donor available Exclusion Criteria:- organ dysfunction

   - HIV positive

View More
View Less

Intervention(s):

procedure: nonmyeloablative allogeneic hematopoietic cell transplant

Not Recruiting

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
BMT Referrals
6507230822

New Trial Alerts

©2024 Stanford Medicine